Education, Science, Technology, Innovation and Life
Open Access
Sign In

Optimization for the therapeutic application of CRISPR/Cas 19 technologies for CHB

Download as PDF

DOI: 10.23977/phpm.2022.020101 | Downloads: 26 | Views: 377

Author(s)

Jasmine Wang 1

Affiliation(s)

1 St. Andrew's Episcopal School, Potomac, MD, 20854

Corresponding Author

Jasmine Wang

ABSTRACT

Hepatitis-B Virus (HBV) is able to escape the immune system by converting HBV DNA into covalently closed circular DNA (cccDNA). This allows an acute Hepatitis B infection to evolve into a chronic Hepatitis B infection which may lead to life-long illness. After the discovery of the CRISPR/Cas9 system, different trials have been done to eliminate the cccDNA but none of them have been very effective.  Based  on  a  previous  study,  I  propose  a  new methodology by which the CRISPR administration by replacing dual Adeno-Associate virus (AAV) vector and add another single-guide RNA (sgRNA) and accorded promoter to intensify the affect.

KEYWORDS

Hepatitis B, CRISPR/Cas9, covalently closed circular DNA, adeno-associated virus, sgRNA, PAMs

CITE THIS PAPER

Jasmine Wang, Optimization for the therapeutic application of CRISPR/Cas 19 technologies for CHB. MEDS Public Health and Preventive Medicine (2022) Vol. 2: 1-5. DOI: http://dx.doi.org/10.23977/phpm.2022.020101.

REFERENCES

[1] Trépo, C., H.L.Y. Chan, and A. Lok,  Hepatitis  B virus  infection.  The Lancet, 2014. 384(9959): p. 2053-2063.
[2] WHO. (2021, July 21). Hepatitis B. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
[3] Liu, J. and D. Fan, Hepatitis B in China. Lancet, 2007. 369(9573): p. 1582-3.
[4] Data Commons.  (2019). People's Republic of China [Infographic].  Data Commons.  https://datacommons.org/place/country/CHN?utm_medium=explore&mprop=count&popt=Person&hl=en 
[5] Seeger, C., & Mason, W. S. (2000). Hepatitis B virus biology. Microbiology and molecular biology reviews : MMBR, 64(1), 51–68.https://doi.org/10.1128/MMBR.64.1.51-68.2000
[6] CDC. (2020, July 28). Hepatitis B questions and answers for the public. Centers for Disease Control and Prevention.https://www.cdc.gov/hepatitis/hbv/bfaq.htm
[7] Wang, Q., et al., Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment. Front Immunol,
2018. 9: p. 219.
[8] Tu, T., et al., Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. J Virol, 2018. 92(11).
[9] <The  hepatitis  B virus  persists for  decades  after  patients'  recovery from  acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.pdf>.
[10] Wang, S., et al., Increasing Coverage of Hepatitis B Vaccination in China: A Systematic Review of Interventions and Implementation Experiences. Medicine (Baltimore), 2016. 95(19): p. e3693.
[11] <A   Programmable   Dual-RNA–Guided   DNA   Endonuclease   in   Adaptive   Bacterial Immunity.pdf>.
[12] Lundstrom, K., Viral Vectors in Gene Therapy. Diseases, 2018. 6(2).
[13] Stone, D., et al., CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Mol Ther Methods Clin Dev, 2021. 20: p. 258-275.
[14] Cui, Y., et al., Review of CRISPR/Cas9 sgRNA Design Tools. Interdiscip Sci, 2018. 10(2):
p. 455-465.

Downloads: 149
Visits: 10691

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.